Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of Erlangen-Nürnberg Medical School

About this trial

The aim of this study is to observe the mechanisms of dapagliflozin on the renal interstitial tissue and renal perfusion. For this purpose, renal transplanted patients as an excellent model of CKD and high cardiovascular risk (similar to patients in DAPA-CKD study) are included in this study.

The objectives of the study are to analyze the effects of dapagliflozin on renal morphology and renal perfusion in patients with impaired renal function one year after kidney transplantation. This is a randomized (1:1), single centre clinical study. Each patient will be randomly assigned in an unblinded fashion to 10 mg Dapagliflozin or not 9 months after transplantation. At least 48 patients will be randomized and included. The routine renal biopsy taken one year after kidney transplantation will allow us to determine the morphological integrity of peritubular fibroblasts, interstitial inflammatory cell density and investigate markers of inflammation, oxidative stress and nitic oxide synthase expression (iNOS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female and male patients aged between 18 and 75 years

Patients with renal transplant having a stable eGFR, who are in stable condition, 9 months after transplantation, irrespective of their diabetes status

Females of child bearing potential must be using adequate contraceptive precautions

Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit

Disqualifiers

Type 1 diabetes mellitus.

HbA1c > 10%

Use of SGLT-2 inhibitor within the past 2 months

Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 3 months prior to study inclusion.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dapagliflozin 10mg Tab

    Drug

    Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.

Treatment groups

48 Participants
are divided into 2 treatment groups
Group A: DapagliflozinActive comparator 1 intervention
Group B: Standard of careNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

renal morphology - fibroblasts

integrity of peritubular fibroblasts (PDGFRα) assessed from the routine one year follow up biopsy of the renal transplant

Time frame
3 months after randomization
2

renal morphology - inflammation

markers of inflammation (example CD3, CD68, CD163) in the interstitium from the routine one year follow up biopsy of the renal transplant

Time frame
3 months after randomization
3

renal morphology - oxidative stress

markers of oxidative stress (Nox1, 8-OHdG) in the interstitium assessed from the routine one year follow up biopsy of the renal transplant

Time frame
3 months after randomization

Secondary outcomes

1

mRNA Expression profile of transcripts

mRNA Expression profile of transcripts relevant in renal transplantation using the Human Organ Transplant Panel of NanoString including 770 genes.

Time frame
3 months after randomization
2

renal perfusion

renal perfusion of the renal transplant measured by ASL-MRI

Time frame
3 months after randomization
3

central (aortic) systolic pressurepulse pressure

central (aortic) systolic pressure and pulse pressure

Time frame
3 months after randomization
4

pulse pressure

pulse pressure

Time frame
3 months after randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.